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D-Penicillamine, an amino acid analogue of cysteine, has been shown to inhibit the transactivation of HIV-1 LTR by 
the transactivator protein, tat protein. The transactivation was studied in Jurkat cells co-transfected with plasmids con- 
taining HIV-LTR sequences fused to the bacterial chloramphenicol acetyhransferase (CAT) gene and HIV tar gene. The 
expression of CAT activity was a measure of transactivation of LTR by the tat protein. Incubation of transfected Jurkat 
cells with D-penicillamine led to inhibition of CAT activity. This inhibition was found to be concentration-dependent; 
more than 90% inhibition of chloramphenicol acetylation was seen in extracts prepared from cultures incubated with 
40 pg/ml of D-penicillamine. Earlier experiments have shown that D-penicillamine at 40 pg/ml can completely inhibit 
HIV-I (HTLV-III B) replication in H9 cells [(1986) Drug Res. 36, 1841861. These results suggest that inhibition of trans- 
activation may be the molecular mechanism involved in the inhibition of HIV-I replication by D-penicillamine. 
D-Penicillamine; HIV-I; Transactivation; tat protein: Azidothymidine; AIDS 
1. INTRODUCTION 
Human immunodeficiency virus type 1 (HIV-l) 
is the major cause of acquired immunodeficiency 
syndrome (AIDS). It is a retrovirus but differs 
from most known animal retroviruses in the com- 
plexity of its genomic organization. In addition to 
the known gag, pal and env genes, HIV-l has at 
least five more genes that contribute to a system 
regulating replication and infectivity of the virus. 
One of these genes, tat, appears to play a central 
role in viral gene expression and replication 
[l-l 11. This suggests that transactivation may be 
an ideal target for potential anti-HIV agents in 
AIDS therapy. 
Transactivator is the protein product of the tat 
gene, which has been identified as a 15 kDa 
polypeptide in HIV-infected cells requiring only 56 
amino acids for its activity. The domain essential 
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for transactivation has some characteristic features 
which are suggestive of a potential nucleic acid- 
binding protein. Firstly, the functional domain in 
tat protein has an abundance of basic over acidic 
residues (16: 3), which could mediate binding to 
the negatively charged backbone of a DNA seg- 
ment, designated as the TAR sequence located 
within the HIV-l LTR. Secondly, this region also 
contains a cluster of seven cysteine residues which 
may comprise a metal-binding domain important 
to nucleic acid binding. The differential ability of 
HIV-l (tat) and HIV-2 (tat) to transactivate some 
of the same LTRs [IO] supports the binding of tat 
protein to specific sequences in LTR. 
Here, we investigated the effect of D- 
penicillamine on the transactivation of HIV-l 
(LTR) by the tat protein. The studies were carried 
out in Jurkat cells which were co-transfected with 
plasmids containing HIV-l (LTR) and tat gene se- 
quences. For measuring transactivation, the HIV-l 
(LTR) was fused to the indicator gene, chloram- 
phenicol acetyltransferase (CAT). The transactiva- 
tion of the LTR-linked CAT gene was measured by 
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conversion of chloramphenicol to its acetylated 
forms by the enzyme synthesized in transfected 
cells. 
2. MATERIALS AND METHODS 
D-Penicillamine was a synthetic product obtained from 
ASTA Pharma (Frankfurt). Azidothymidine (3 ‘-azido-3 ’ - 
deoxythymidine, AzT) and diethylaminoethyl-dextran (DEAE- 
dextran, M, 500000) were purchased from Sigma (Deisenhofen). 
The culture medium (RPM1 1640) and fetal calf serum were 
supplied by Gibco (Eggenstein). “C-labeled chloramphenicol 
(40-60 mCi/mmol) was obtained from NEN/Dupont 
(Dreieich). Thin-layer chromatography sheets were from Merck 
(DC plastikfolien no. 5748, Kieselgel 60; Darmstadt). 
2.1. Plasmids 
The HIV-l LTR (clone C15) and fat gene (clone 1) were clon- 
ed by way of cDNA cloning, using poly(A)-selected RNA from 
HIV-l (BH 10) infected H9 cells. The Cl5CAT was obtained 
by inserting clone 15 DNA into pSVO-CAT at the Hind111 site 
[12,13], and resulting plasmid was termed pCl5CAT. The 
plasmid pCV1 was obtained by inserting viral cDNA containing 
the tat gene (clone 1) into the mammalian expression vector 
pCV [14] which contains duplicated SV40 replication origin 
(off), adenovirus major late promotor, splice sites from 
adenovirus and mouse immunoglobulin genes, mouse 
dihydrofolate reductase cDNA, and SV40 polyadenylation 
signal. The plasmid pSV2CAT contains SV40 early promotor 
5’ to the CAT gene [15]. 
2.2. Transfection and CAT assays 
About 1 x IO’ Jurkat cells were washed with serum-free 
medium and incubated at 37°C for 1 h in 1 ml serum-free 
medium containing 50 mM Tris-HCl (pH 7.3). DEAE-dextran 
(250pg/ml) and 15pg of each plasmid DNA, pCVl and 
pCl5CAT or pSV2CAT. The cells were then washed with 
growth medium (without serum) and incubated in 10 ml serum- 
containing medium at 37°C. At this time, the test compounds, 
D-penicillamine or AzT, were added at the desired concentra- 
tions in parallel batches. 48 h after the incubations, cells were 
washed with phosphate-buffered saline and suspended in 80 pl 
of 0.25 M Tris-HCl (pH 7.8), and cellular extracts were 
prepared by three cycles of freezing (in ethanol and dry ice) and 
thawing (37°C). All cellular extracts were adjusted to equal pro- 
tein concentration. The activity of CAT was measured by in- 
cubating 20-p] aliquots of extracts with ‘?-labeled 
chloramphenicol (Cm) and 2.5 mM acetyl-CoA at 37°C for 1 h, 
and separating the acetylated chloramphenicol (AcCm) from 
the unacetylated form by ascending thin-layer chromatography. 
The chromatogram was autoradiographed and spots cut from 
the plate were quantitated by scintillation counting. All 
transfections were performed in triplicate for each set of ex- 
periments. 
3. RESULTS 
Potential metal-binding domains are known to 
exist in proteins which interact with nucleic acids. 
Fig. 1. Effect of D-penicillamine on LTR (HIV-l)-directed CAT 
expression catalyzed by tat protein. About 1 x 10’ Jurkat cells 
were transfected by the DEAE-dextran protocol with 15 gg each 
of pC15 (LTR-CAT) and pCV1 (tat) plasmids. Transfected cells 
were cultivated for 48 h without D-penicillamine (lane I), or 
with the following concentrations of D-penicillamine: (lanes) 2, 
lOpg/ml; 3, 20ag/ml; 4, 30pg/ml; 5, 40pg/ml. After 48 h, 
cell extracts were analyzed for CAT activity by the conversion 
of labeled chloramphenicol (Cm) to acetylated chloramphenicol 
(AcCm). Acetylated and unacetylated forms were separated by 
ascending thin-layer chromatography. Shown is a 20 h exposure 
of the thin-layer plate to X-ray film (Kodak X-Omat S) at 
- 80°C. 
These proteins have a characteristic feature in 
possessing cysteine-rich regions at the binding site 
[16]. HIV-l has two proteins which exhibit this 
character, and are known to bind to nucleic acids. 
Firstly, the nucleic-acid binding protein encoded 
by the gag gene, and secondly, the transactivator 
protein encoded by the tat gene [ 171. Since tat is 
essential for HIV-l replication, it provides an at- 
tractive target for drug design. D-Penicillamine, an 
amino acid analog of cysteine, is known to interact 
with cysteine-rich proteins [l&-20]. This interac- 
tion occurs by the formation of interdisulfide 
bonds between D-penicillamine and cysteine or 
cystine, and such penicillamine-protein complexes 
are highly stable as suggested by the fact that cys- 
teine or cystine added after D-penicillamine cannot 
remove the drug from proteins [21]. The chelation 
of metals by D-penicillamine is the basis of its ap- 
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Table 1 
Effect of D-penicillamine on the LTR (HIV-1)-directed 
expression catalyzed by the tat protein 
Experiment Percent conversion of 
chloramphenicol to acetylated 
forms 
Without D-penicillamine 
(control) 23.33 f 3.5 (100) 
With D-penicillamine 
(_ug/ml) 
10 2.9 f 0.33 (12.4) 
20 1.97 + 0.29 (8.4) 
30 1.46 + 0.22 (6.25) 
40 0.97 f 0.15 (4.15) 
Percent conversion of chloramphenicol to acetylated forms was 
calculated by dividing the total number of counts in the AcCm 
region (cf. fig.]) with that found in the Cm and AcCm regions. 
This coefficient multiplied by 100 is shown as the percent value 
for the acetylated product. Values are means * SD for 3 
independent transfection experiments. Experimental proce- 
dures were the same as described in fig. 1 and section 2. Values 
in parentheses indicate the percent of control, with the control 
being taken as 100 
plication in the treatment of Wilson’s disease [22]. 
The interaction of D-penicillamine with cysteine- 
rich proteins and its chelating potential motivated 
us to examine its effect on the replication of 
HIV-l. D-Penicillamine has been shown to block 
HIV replication in vitro [23] and it suppresses virus 
replication in AIDS patients [24-261. To in- 
vestigate the mechanism of anti-HIV activity we 
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Fig.2. Measurement of CAT expression in Jurkat cells 
transfected with pCVl(tat) + pSVOCAT (lane 1). pSV2-CAT 
alone (lane 2), pCVl(tat) + pSV2CAT (lane 3); lane 4 has the 
same experimental set up as lane 3, except that cells were 
cultivated with D-penicillamine (40 pg/ml). Experimental 
procedures were the same as described in fig.1 and section 2. 
Fig.3. Effect of azidothymidine (3 ’ -azido-3 ’ -deoxythymidine: 
AzT) on LTR (HIV-I)-directed CAT expression catalyzed by tat 
protein. Transfected Jurkat cells were cultivated without AzT 
(lane I), or with the following concentrations of AzT: lane 2, 
10 PM; lane 3, 25 pM. All other procedures were as described 
in fig.1 and section 2. 
have studied the effect of D-penicillamine on HIV- 
LTR transactivation by the tat protein. 
Jurkat cells transfected with plasmids pC 1 SCAT 
and pCV1 express CAT, as shown in fig. 1 (lane 1). 
Cells incubated with different concentrations of D- 
penicillamine (lo-40 pg/ml) exhibit concentra- 
tion-dependent inhibition of CAT expression 
(lanes 2-5). The quantitative values for the 
amounts of acetylated chloramphenicol in each set 
of experiments are listed in table 1. As follows 
from these results, more than 90% inhibition of 
CAT expression is shown by D-penicillamine at 
40,~g/ml. Considering the fact that the mean 
deviation between three sets of experiments for 
each probe was in the range 12-15070, we could 
consider almost a total inhibition of CAT produc- 
tion at 40,~g/ml. 
In an earlier communication [23] we reported 
the cytotoxicity of D-penicillamine towards H-9 
cells. We found that concentrations up to 
200 pug/ml of D-penicillamine have no effect on the 
growth of H-9 cells; at 500pg/ml 32% inhibition 
of cell growth was observed. Thus, the concentra- 
tion which totally inhibits transactivation has no 
effect on the growth of Jurkat cells. 
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To document the specificity of our co- 
transfection assay, we designed experiments where 
the cells were transfected with the tat clone (pCV1) 
and other plasmids without the HIV-LTR region, 
such as pSVO-CAT and pSV2CAT. As follows 
from fig.2, there is no CAT activity in cells 
transfected with pSVOCAT and pCV1 (lane l), 
pSV2CAT alone (lane 2), pSV2CAT and pCV1 
(lane 3). The experiment depicted in lane 4 had the 
same set-up as in lane 3, except that these cells were 
treated with D-penicillamine (40 pg/ml). These 
results confirm that LTR sequences of HIV-l are 
necessary for the transactivating function of tat 
protein. 
Recently, Felber and Pavlakis [27] have reported 
a quantitative bioassay for HIV-l based on 
transactivation, using human indicator lymphoid 
cell lines that contain integrated copies of HIV 
(LTR)-CAT. This system has been suggested by 
them for monitoring anti-HIV drugs, and one of 
the drugs which responded inhibitorily in this 
system was azidothymidine (AzT). It was sug- 
gested that anti-HIV activity of AzT [28,29] may 
not be due only to inhibition of reverse transcrip- 
tion [30], and that other effects may also be involv- 
ed. For this reason, we have tested AzT in our 
system to document that AzT does not influence 
the transactivation process directly or indirectly. 
As follows from fig.3, there was no effect of AzT 
on the expression of CAT activity in our ex- 
periments (lanes 2,3). Quantitative measurements 
for the acetylation of chloramphenicol showed 
16% inhibition at 1OpM and 9% inhibition at 
25 PM AzT. 
4. DISCUSSION 
We have shown that D-penicillamine inhibits the 
transactivation of HIV-l LTR by tat protein. Since 
D-penicillamine was added to the cells after the 
transfection protocol, the possibility of its in- 
tervention in plasmid DNA uptake is ruled out. 
The control experiments with plasmids without 
HIV-l LTR sequences and with AzT further sup- 
port this statement. Thus, the effects reported here 
clearly show that D-penicillamine blocks the in- 
teraction between tat protein and HIV-l LTR 
which is a requisite for the expression of the CAT 
gene. 
We can consider several possible models to ex- 
plain how D-penicillamine blocks this interaction. 
Frankel et al. [17] have recently shown that the 
transactivating protein from HIV-l forms a metal- 
linked dimer with metal ions bridging cysteine-rich 
regions from each monomer. Ultraviolet absorp- 
tion spectra showed that tat protein binds two 
Zn*+ or two Cd*+ per monomer. Based on the 
chemical reactivities of D-penicillamine, we can 
postulate a bimodal function of D-penicillamine to 
block the transactivation process in HIV-l. The 
chelation of metal ions will affect the formation of 
tat dimer, if it turns out to be the requirement for 
in vivo binding to DNA. Even if we consider the 
monomer model of Patarca and Haseltine [3 11, the 
metal binding is a requisite for nucleic acid binding 
of tat protein. On the other hand, D-penicillamine 
could form stable interdisulfide bonds with the 
cysteine residues at the functional binding domain. 
This will affect the secondary structure of tat pro- 
tein and also occupy the sites needed for metal 
binding. Even with taking into account that metal 
binding is not important for the transactivating 
event, the latter reaction will completely abolish 
the biochemical functions of tat protein. 
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